Biomanufacturing Media

1. Protecting Biopharma Manufacturing Supply Chains 2/5/2026

   In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers and staying agile during periods of change in the industry.

2. Building Resilience In Biomanufacturing Operations 2/5/2026

   In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists share their thoughts on what it means to be resilient and how organizations can embody resilience in their biomanufacturing, which in part requires agility and preparation for the worst-case scenario. The panel was in agreement that earlier-phase companies have the highest opportunity to bake resilience into their operations.

3. How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets? 2/5/2026

   In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also discuss the short- to long-term impact of efforts to onshore biomanufacturing.

4. How Is U.S. Policy Reshaping Global Biomanufacturing Operations? 2/5/2026

   In this opening segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein speak candidly about how U.S. tariffs are affecting the global operating environment.

5. Viral Clearance Strategies For Monoclonal Antibodies And Proteins 1/30/2026

   Guidance on designing viral clearance studies using regulatory-aligned, risk‑based strategies, optimized assays, and real case examples for safe, efficient biologics development.

6. Drug Product Development: Preclinical To Commercial 1/26/2026

   Watch a unified roadmap for drug product development, outlining phase‑appropriate studies, QTTP importance, and key requirements from preclinical stages through commercialization.

7. Developability Assessment And Early Formulation Studies 1/26/2026

   Early developability and pre‑formulation screening build strong biophysical data, reduce late‑stage risks, support candidate selection, and streamline biologics development toward clinical success.

8. Five Practical Considerations To Move From Concept To Clinic 12/17/2025

   Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.

9. Hear From The Experts: LNPs Driving The Future Of Cell Therapy 12/12/2025

   Explore how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

10. Manufacturing Made More Robust And Customer-Centric 12/11/2025

    Discover how regional manufacturing, risk-aware practices, and agile strategies are reshaping supply chains to deliver resilience, transparency, and sustainability in today’s complex global environment.